FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa - Takeaways - MDSpire

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 2 min

Share

  • 1

    The FDA has approved secukinumab for adolescents aged 12 and older with moderate to severe hidradenitis suppurativa.

  • 2

    Secukinumab is the only interleukin-17A inhibitor approved for pediatric patients with hidradenitis suppurativa.

  • 3

    This approval provides a new biologic treatment option for adolescents with limited options for managing HS.

  • 4

    Hidradenitis suppurativa is a chronic inflammatory disorder that often begins during adolescence.

  • 5

    The approval was supported by adult HS studies and pediatric clinical trial data from other indications.

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Association between the albumin-to-lymphocyte ratio and short-term mortality in critically Ill pediatric patients: a retrospective cohort study and machine learning analysis

Insights into epidemiological and clinical burden of bronchiolitis among hospitalized children: a call for preventive interventions